pdl1 antibody
PDL1 Antibody [5H6] |
|||
RF16033-002mg | ProSci | 0.02 mg | 229.7 EUR |
Description: PD-L1 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antigen-presenting cells (APC) (1). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC (2). PD-1 can bind two different but related ligands, PD-L1 and PD-L2. PD-L1 is a B7-related protein that inhibits cell-mediated immune responses by reducing the secretion of IL-2 and IL-10 from memory T cells (3). This suggests that PD-L1 may be useful in reducing allogenic CD4+ memory T-cell responses to endothelial cells, thereby reducing the likelihood of host immune responses to allografts. PD-L1 also functions as an immune checkpoint protein, and multiple anti-PD-L1 antibodies are currently in phase II and III clinical trials, with one antibody already approved for the treatment of cancer (4). |
|||
PDL1 Antibody [5H6] |
|||
RF16033-01mg | ProSci | 0.1 mg | 594.26 EUR |
Description: PD-L1 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antigen-presenting cells (APC) (1). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC (2). PD-1 can bind two different but related ligands, PD-L1 and PD-L2. PD-L1 is a B7-related protein that inhibits cell-mediated immune responses by reducing the secretion of IL-2 and IL-10 from memory T cells (3). This suggests that PD-L1 may be useful in reducing allogenic CD4+ memory T-cell responses to endothelial cells, thereby reducing the likelihood of host immune responses to allografts. PD-L1 also functions as an immune checkpoint protein, and multiple anti-PD-L1 antibodies are currently in phase II and III clinical trials, with one antibody already approved for the treatment of cancer (4). |
|||
PDL1 Antibody [2D6] |
|||
RF16036-002mg | ProSci | 0.02 mg | 229.7 EUR |
Description: PD-L1 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antigen-presenting cells (APC) (1). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC (2). PD-1 can bind two different but related ligands, PD-L1 and PD-L2. PD-L1 is a B7-related protein that inhibits cell-mediated immune responses by reducing the secretion of IL-2 and IL-10 from memory T cells (3). This suggests that PD-L1 may be useful in reducing allogenic CD4+ memory T-cell responses to endothelial cells, thereby reducing the likelihood of host immune responses to allografts. PD-L1 also functions as an immune checkpoint protein, and multiple anti-PD-L1 antibodies are currently in phase II and III clinical trials, with one antibody already approved for the treatment of cancer (4). |
|||
PDL1 Antibody [2D6] |
|||
RF16036-01mg | ProSci | 0.1 mg | 594.26 EUR |
Description: PD-L1 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antigen-presenting cells (APC) (1). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC (2). PD-1 can bind two different but related ligands, PD-L1 and PD-L2. PD-L1 is a B7-related protein that inhibits cell-mediated immune responses by reducing the secretion of IL-2 and IL-10 from memory T cells (3). This suggests that PD-L1 may be useful in reducing allogenic CD4+ memory T-cell responses to endothelial cells, thereby reducing the likelihood of host immune responses to allografts. PD-L1 also functions as an immune checkpoint protein, and multiple anti-PD-L1 antibodies are currently in phase II and III clinical trials, with one antibody already approved for the treatment of cancer (4). |
|||
PDL1 Antibody [1D7] |
|||
RF16038-002mg | ProSci | 0.02 mg | 229.7 EUR |
Description: PD-L1 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antigen-presenting cells (APC) (1). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC (2). PD-1 can bind two different but related ligands, PD-L1 and PD-L2. PD-L1 is a B7-related protein that inhibits cell-mediated immune responses by reducing the secretion of IL-2 and IL-10 from memory T cells (3). This suggests that PD-L1 may be useful in reducing allogenic CD4+ memory T-cell responses to endothelial cells, thereby reducing the likelihood of host immune responses to allografts. PD-L1 also functions as an immune checkpoint protein, and multiple anti-PD-L1 antibodies are currently in phase II and III clinical trials, with one antibody already approved for the treatment of cancer (4). |
|||
PDL1 Antibody [1D7] |
|||
RF16038-01mg | ProSci | 0.1 mg | 594.26 EUR |
Description: PD-L1 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antigen-presenting cells (APC) (1). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC (2). PD-1 can bind two different but related ligands, PD-L1 and PD-L2. PD-L1 is a B7-related protein that inhibits cell-mediated immune responses by reducing the secretion of IL-2 and IL-10 from memory T cells (3). This suggests that PD-L1 may be useful in reducing allogenic CD4+ memory T-cell responses to endothelial cells, thereby reducing the likelihood of host immune responses to allografts. PD-L1 also functions as an immune checkpoint protein, and multiple anti-PD-L1 antibodies are currently in phase II and III clinical trials, with one antibody already approved for the treatment of cancer (4). |
|||
PDL1 Antibody [8E12] |
|||
RF16032-002mg | ProSci | 0.02 mg | 229.7 EUR |
Description: PD-L1 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antigen-presenting cells (APC) (1). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC (2). PD-1 can bind two different but related ligands, PD-L1 and PD-L2. PD-L1 is a B7-related protein that inhibits cell-mediated immune responses by reducing the secretion of IL-2 and IL-10 from memory T cells (3). This suggests that PD-L1 may be useful in reducing allogenic CD4+ memory T-cell responses to endothelial cells, thereby reducing the likelihood of host immune responses to allografts. PD-L1 also functions as an immune checkpoint protein, and multiple anti-PD-L1 antibodies are currently in phase II and III clinical trials, with one antibody already approved for the treatment of cancer (4). |
|||
PDL1 Antibody [8E12] |
|||
RF16032-01mg | ProSci | 0.1 mg | 594.26 EUR |
Description: PD-L1 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antigen-presenting cells (APC) (1). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC (2). PD-1 can bind two different but related ligands, PD-L1 and PD-L2. PD-L1 is a B7-related protein that inhibits cell-mediated immune responses by reducing the secretion of IL-2 and IL-10 from memory T cells (3). This suggests that PD-L1 may be useful in reducing allogenic CD4+ memory T-cell responses to endothelial cells, thereby reducing the likelihood of host immune responses to allografts. PD-L1 also functions as an immune checkpoint protein, and multiple anti-PD-L1 antibodies are currently in phase II and III clinical trials, with one antibody already approved for the treatment of cancer (4). |
|||
PDL1 Antibody [6H10] |
|||
RF16035-002mg | ProSci | 0.02 mg | 229.7 EUR |
Description: PD-L1 plays a critical role in induction and maintenance of immune tolerance to self. As a ligand for the inhibitory receptor PDCD1/CD279, PD-L1 modulates the activation threshold of T-cells and limits T-cell effector response (1). The PDCD1/CD279-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and facilitate tumor survival (2,3). Through a yet unknown activating receptor, it may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10) (4). |
|||
PDL1 Antibody [6H10] |
|||
RF16035-01mg | ProSci | 0.1 mg | 594.26 EUR |
Description: PD-L1 plays a critical role in induction and maintenance of immune tolerance to self. As a ligand for the inhibitory receptor PDCD1/CD279, PD-L1 modulates the activation threshold of T-cells and limits T-cell effector response (1). The PDCD1/CD279-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and facilitate tumor survival (2,3). Through a yet unknown activating receptor, it may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10) (4). |
|||
PDL1 Antibody [1F11] |
|||
RF16037-002mg | ProSci | 0.02 mg | 229.7 EUR |
Description: PD-L1 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antigen-presenting cells (APC) (1). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC (2). PD-1 can bind two different but related ligands, PD-L1 and PD-L2. PD-L1 is a B7-related protein that inhibits cell-mediated immune responses by reducing the secretion of IL-2 and IL-10 from memory T cells (3). This suggests that PD-L1 may be useful in reducing allogenic CD4+ memory T-cell responses to endothelial cells, thereby reducing the likelihood of host immune responses to allografts. PD-L1 also functions as an immune checkpoint protein, and multiple anti-PD-L1 antibodies are currently in phase II and III clinical trials, with one antibody already approved for the treatment of cancer (4). |
|||
PDL1 Antibody [1F11] |
|||
RF16037-01mg | ProSci | 0.1 mg | 594.26 EUR |
Description: PD-L1 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antigen-presenting cells (APC) (1). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC (2). PD-1 can bind two different but related ligands, PD-L1 and PD-L2. PD-L1 is a B7-related protein that inhibits cell-mediated immune responses by reducing the secretion of IL-2 and IL-10 from memory T cells (3). This suggests that PD-L1 may be useful in reducing allogenic CD4+ memory T-cell responses to endothelial cells, thereby reducing the likelihood of host immune responses to allografts. PD-L1 also functions as an immune checkpoint protein, and multiple anti-PD-L1 antibodies are currently in phase II and III clinical trials, with one antibody already approved for the treatment of cancer (4). |
|||
PDL1 Antibody [8E12] (biotin) |
|||
RF16032-biotin-002mg | ProSci | 0.02 mg | 229.7 EUR |
Description: PD-L1 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antigen-presenting cells (APC) (1). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC (2). PD-1 can bind two different but related ligands, PD-L1 and PD-L2. PD-L1 is a B7-related protein that inhibits cell-mediated immune responses by reducing the secretion of IL-2 and IL-10 from memory T cells (3). This suggests that PD-L1 may be useful in reducing allogenic CD4+ memory T-cell responses to endothelial cells, thereby reducing the likelihood of host immune responses to allografts. PD-L1 also functions as an immune checkpoint protein, and multiple anti-PD-L1 antibodies are currently in phase II and III clinical trials, with one antibody already approved for the treatment of cancer (4). |
|||
PDL1 Antibody [8E12] (biotin) |
|||
RF16032-biotin-01mg | ProSci | 0.1 mg | 594.26 EUR |
Description: PD-L1 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antigen-presenting cells (APC) (1). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC (2). PD-1 can bind two different but related ligands, PD-L1 and PD-L2. PD-L1 is a B7-related protein that inhibits cell-mediated immune responses by reducing the secretion of IL-2 and IL-10 from memory T cells (3). This suggests that PD-L1 may be useful in reducing allogenic CD4+ memory T-cell responses to endothelial cells, thereby reducing the likelihood of host immune responses to allografts. PD-L1 also functions as an immune checkpoint protein, and multiple anti-PD-L1 antibodies are currently in phase II and III clinical trials, with one antibody already approved for the treatment of cancer (4). |
|||
PDL1/ Rat PDL1 ELISA Kit |
|||
ELA-E0513r | Lifescience Market | 96 Tests | 1063.2 EUR |
PDL1 ELISA Matched Antibody Pair (Risk Free) |
|||
RFP-0303 | ProSci | 1 Set | 745.8 EUR |
Description: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antigen-presenting cells (APC). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC. PD-1 can bind two different but related ligands, PD-L1 and PD-L2. PD-L1 is a B7-related protein that inhibits cell-mediated immune responses by reducing the secretion of IL-2 and IL-10 from memory T cells. This suggests that PD-L1 may be useful in reducing allogenic CD4+ memory T-cell responses to endothelial cells, thereby reducing the likelihood of host immune responses to allografts.ProSci's Risk-FreeTM antibodies are mouse monoclonal antibodies made to improve in vivo studies. Unlike antibodies developed using proteins made in yeast or bacteria, Risk-FreeTM antibodies are developed with antigens expressed in mammalian cell lines, giving the most native post-translational modifications to the protein. Validated for flow cytometry and ELISA Rigorously tested for the following applications: Immunoblot Immunohistochemistry Immunocytochemistry Immunofluorescence Multiple antibodies per target allowing the user to choose the best antibody for their application Available individually or as a set Risk-FreeTM means they are guaranteed to work for their approved applications |
|||
PDL1 ELISA Matched Antibody Pair (Risk Free) |
|||
RFP-0306 | ProSci | 1 Set | 745.8 EUR |
Description: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antigen-presenting cells (APC). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC. PD-1 can bind two different but related ligands, PD-L1 and PD-L2. PD-L1 is a B7-related protein that inhibits cell-mediated immune responses by reducing the secretion of IL-2 and IL-10 from memory T cells. This suggests that PD-L1 may be useful in reducing allogenic CD4+ memory T-cell responses to endothelial cells, thereby reducing the likelihood of host immune responses to allografts.ProSci's Risk-FreeTM antibodies are mouse monoclonal antibodies made to improve in vivo studies. Unlike antibodies developed using proteins made in yeast or bacteria, Risk-FreeTM antibodies are developed with antigens expressed in mammalian cell lines, giving the most native post-translational modifications to the protein. Validated for flow cytometry and ELISA Rigorously tested for the following applications: Immunoblot Immunohistochemistry Immunocytochemistry Immunofluorescence Multiple antibodies per target allowing the user to choose the best antibody for their application Available individually or as a set Risk-FreeTM means they are guaranteed to work for their approved applications |
|||
PDL1 ELISA Matched Antibody Pair (Risk Free) |
|||
RFP-0307 | ProSci | 1 Set | 752.1 EUR |
Description: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antigen-presenting cells (APC). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC. PD-1 can bind two different but related ligands, PD-L1 and PD-L2. PD-L1 is a B7-related protein that inhibits cell-mediated immune responses by reducing the secretion of IL-2 and IL-10 from memory T cells. This suggests that PD-L1 may be useful in reducing allogenic CD4+ memory T-cell responses to endothelial cells, thereby reducing the likelihood of host immune responses to allografts.ProSci's Risk-FreeTM antibodies are mouse monoclonal antibodies made to improve in vivo studies. Unlike antibodies developed using proteins made in yeast or bacteria, Risk-FreeTM antibodies are developed with antigens expressed in mammalian cell lines, giving the most native post-translational modifications to the protein. Validated for flow cytometry and ELISA Rigorously tested for the following applications: Immunoblot Immunohistochemistry Immunocytochemistry Immunofluorescence Multiple antibodies per target allowing the user to choose the best antibody for their application Available individually or as a set Risk-FreeTM means they are guaranteed to work for their approved applications |
|||
pEGFP- PDL1 |
|||
PVT10283 | Lifescience Market | 2 ug | 361.2 EUR |
Programmed Cell Death Protein 1 Ligand 1 (PDL1) Antibody (Biotin) |
|||
20-abx274655 | Abbexa |
|
|
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
BNC942746-100 | Biotium | 100uL | 279.6 EUR |
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF594 conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
BNC942746-500 | Biotium | 500uL | 654 EUR |
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF594 conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
BNC802746-100 | Biotium | 100uL | 279.6 EUR |
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF680 conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
BNC802746-500 | Biotium | 500uL | 654 EUR |
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF680 conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
BNC702746-100 | Biotium | 100uL | 279.6 EUR |
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF770 conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
BNC702746-500 | Biotium | 500uL | 654 EUR |
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF770 conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
BNC882746-100 | Biotium | 100uL | 279.6 EUR |
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF488A conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
BNC882746-500 | Biotium | 500uL | 654 EUR |
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF488A conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
BNC812746-100 | Biotium | 100uL | 279.6 EUR |
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF680R conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
BNC812746-500 | Biotium | 500uL | 654 EUR |
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF680R conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
BNC402746-100 | Biotium | 100uL | 279.6 EUR |
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF640R conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
BNC402746-500 | Biotium | 500uL | 654 EUR |
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF640R conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
BNC052746-100 | Biotium | 100uL | 279.6 EUR |
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF405M conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
BNC052746-500 | Biotium | 500uL | 654 EUR |
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF405M conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
BNC042746-100 | Biotium | 100uL | 279.6 EUR |
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF405S conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
BNC042746-500 | Biotium | 500uL | 654 EUR |
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF405S conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
BNCAP2746-100 | Biotium | 100uL | 279.6 EUR |
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
BNCAP2746-500 | Biotium | 500uL | 654 EUR |
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
BNCA2746-250 | Biotium | 250uL | 472.8 EUR |
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), APC conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
BNCP2746-250 | Biotium | 250uL | 472.8 EUR |
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), PerCP conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
BNCR2746-250 | Biotium | 250uL | 472.8 EUR |
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), RPE conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
BNCH2746-100 | Biotium | 100uL | 279.6 EUR |
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
BNCH2746-500 | Biotium | 500uL | 654 EUR |
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
BNCB2746-100 | Biotium | 100uL | 279.6 EUR |
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), Biotin conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
BNCB2746-500 | Biotium | 500uL | 654 EUR |
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), Biotin conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
BNUB2746-100 | Biotium | 100uL | 316.8 EUR |
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), Concentration: 0.2mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
BNUB2746-500 | Biotium | 500uL | 615.6 EUR |
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), Concentration: 0.2mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
BNUM2746-50 | Biotium | 50uL | 486 EUR |
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), 1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
BNC472746-100 | Biotium | 100uL | 279.6 EUR |
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF647 conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
BNC472746-500 | Biotium | 500uL | 654 EUR |
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF647 conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
BNC552746-100 | Biotium | 100uL | 279.6 EUR |
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF555 conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
BNC552746-500 | Biotium | 500uL | 654 EUR |
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF555 conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
BNC612746-100 | Biotium | 100uL | 279.6 EUR |
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF660R conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
BNC612746-500 | Biotium | 500uL | 654 EUR |
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF660R conjugate, Concentration: 0.1mg/mL |
|||
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746) Antibody |
|||
BNC432746-100 | Biotium | 100uL | 279.6 EUR |
Description: Primary antibody against PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF543 conjugate, Concentration: 0.1mg/mL |